The identification of glioblastoma-associated, fucose-containing glycoproteins induced by retinoic acid.
We have used a tumorigenic glioblastoma cell line, SNB-19, as a model system to identify fucose-containing glycoprotein candidates for tumor suppressor function. Glycoproteins were analyzed after treatment with a variety of chemical differentiating agents by two-dimensional SDS-PAGE, followed by electroblotting and visualization using the fucose-specific lectin, Ulex europeaus I. Approximately 25 fucose-containing glycoproteins (FUCGLAPs) were routinely visualized in control extracts using 60-70 micrograms of protein per gel and staining with Vectastain ABC kits. Retinoic acid induced the most marked change in FUCGLAP expression, causing a fivefold increase in one FUCGLAP (M(r) = 125 kDa, pI = 6.6). Neither butyric acid, dibutyryl cAMP, nor combinations of these compounds gave a similar result. Using this model system and analytical approach, it should be possible to identify, isolate, and evaluate glycoprotein oligosaccharides for their tumor modulating capability.
VanderMeulen
D L
DL
Chicago Institute for Neurosurgery and Neuroresearch, IL 60614.
Prasad
V V
VV
Moskal
J R
JR
D003994:Bucladesine / Q000494:pharmacology; D002087:Butyrates / Q000494:pharmacology; D020148:Butyric Acid; D002454:Cell Differentiation; D002460:Cell Line; D004305:Dose-Response Relationship, Drug; D015180:Electrophoresis, Gel, Two-Dimensional; D004591:Electrophoresis, Polyacrylamide Gel; D005643:Fucose / Q000032:analysis / Q000378:metabolism*; D005909:Glioblastoma / Q000378:metabolism*; D006023:Glycoproteins / Q000096:biosynthesis* / Q000737:chemistry / Q000302:isolation & purification; D006801:Humans; D037102:Lectins; D014212:Tretinoin / Q000494:pharmacology*; D014407:Tumor Cells, Cultured
D002087:Butyrates; D006023:Glycoproteins; D037102:Lectins; D020148:Butyric Acid; D005643:Fucose; D014212:Tretinoin; D003994:Bucladesine